All Stories

  1. The role of N‐terminal pro‐brain natriuretic peptide, chromogranin A, and 5‐hydroxyindoleacetic acid in screening for carcinoid heart disease
  2. Fungal translocation measured by serum 1,3‐ß‐D‐glucan correlates with severity and outcome of liver cirrhosis—A pilot study
  3. Editorial: non‐invasive diagnosis of alcohol‐related steatohepatitis in patients ongoing alcohol withdrawal based on cytokeratin 18 and transient elastography
  4. The macrophage activation marker sCD163 in acute and chronic graft-versus-host disease after pediatric hematopoietic stem cell transplantation
  5. The Prevalence of Inflammatory Bowel Disease in Greenland
  6. Effects of lifestyle intervention on IGF-1, IGFBP-3, and insulin resistance in children with obesity with or without metabolic-associated fatty liver disease
  7. Association between fibrosis markers and kidney function following peptide receptor radionuclide therapy in patients with neuroendocrine tumours
  8. Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding
  9. Impaired Glucagon-Mediated Suppression of VLDL-Triglyceride Secretion in Individuals With Metabolic Dysfunction–Associated Fatty Liver Disease (MAFLD)
  10. Development and validation of the Cirrhotic Ascites Severity model—A patient‐reported outcome‐based model to predict 1‐year mortality
  11. Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease
  12. Fatigue and quality of life in patients with neuroendocrine neoplasia
  13. Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients
  14. Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumours and differentiation from small intestinal neuroendocrine tumours
  15. Non-alcoholic fatty liver disease in patients with type 2 diabetes in Greenland: a register-based cross-sectional study
  16. Clinical Progression of Metabolic-Associated Fatty Liver Disease Is Rare in a Danish Tertiary Liver Center
  17. Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases
  18. The galactose elimination capacity test to monitor liver disease course in patients with Wilson’s disease
  19. Prognosis of Patients with Bronchopulmonary Neuroendocrine Neoplasms in a Tertiary Neuroendocrine Tumor Centre of Excellence
  20. Metformin Stimulates Intestinal Glycolysis and Lactate Release: A single‐Dose Study of Metformin in Patients With Intrahepatic Portosystemic Stent
  21. Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis
  22. Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults
  23. Abdominal investigations in the year preceding a diagnosis of abdominal cancer: A register-based cohort study in Denmark
  24. Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
  25. Cognitive Impairment In Stable Wilson Disease Across Phenotype.
  26. Core liver homeostatic co-expression networks are preserved but respond to perturbations in an organism- and disease-specific manner
  27. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis
  28. Cancer suspicion, referral to cancer patient pathway and primary care interval: a survey and register study exploring 10 different types of abdominal cancer
  29. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma
  30. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
  31. Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis
  32. Interferon lambda 4 genotype and pathway in alcoholic hepatitis
  33. Efficacy of Dietary Manipulations for Depleting Intrahepatic Triglyceride Content: Implications for the Management of Non-alcoholic Fatty Liver Disease
  34. Increased occurrence of liver and gastrointestinal diseases and anaemia in women with Turner syndrome – a nationwide cohort study
  35. No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics on Bacterial Translocation or Hepatic and Systemic Inflammation
  36. Administrative coding in electronic health care record‐based research of NAFLD: an expert panel consensus statement
  37. Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study
  38. CELL-FREE DNA AND CLINICAL CHARACTERISTICS IN PATIENTS WITH SMALL INTESTINAL OR PANCREATIC NEUROENDOCRINE TUMORS
  39. Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis
  40. Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data
  41. Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease
  42. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
  43. Macrophage markers and innate immunity in cirrhosis
  44. Altered balance between collagen formation and degradation after successful direct‐acting antiviral therapy of chronic hepatitis C
  45. First trimester biomarkers for prediction of gestational diabetes mellitus
  46. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS
  47. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma
  48. Combining Tissue and Circulating Tumor DNA Increases the Detection Rate of CTNNB1 Mutation in Hepatocellular Carcinoma
  49. Thrombophilia testing in patients with portal vein thrombosis
  50. One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
  51. A consensus developed morphological re-evaluation of 196 high-grade gastroenteropancreatic neuroendocrine neoplasms and its clinical correlations.
  52. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology
  53. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
  54. Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study
  55. The effect of acute intragastric vs. intravenous alcohol administration on inflammation markers, blood lipids and gallbladder motility in healthy men
  56. 1006P PD-L1, tumor mutational burden, and overall survival among patients undergoing surgical treatment for hepatocellular carcinoma prior to systemic therapy
  57. Letter: improve survival! Place early pre-emptive TIPSS in high-risk variceal bleeders
  58. Early normalization of reduced urea synthesis capacity after direct-acting antiviral therapy in hepatitis C cirrhosis
  59. Progression of non-alcoholic fatty liver disease is rare in a Danish tertiary liver centre
  60. A plasma protein biomarker strategy for detection of small intestinal neuroendocrine tumors
  61. Clinical Efficacy of First and Second Series of Peptide Receptor Radionuclide Therapy in Patients With Neuroendocrine Neoplasm: A Cohort Study
  62. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis
  63. The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson’s disease
  64. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
  65. Liver-related effects of chronic hepatitis C antiviral treatment
  66. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy
  67. Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute‐on‐chronic liver failure and acute decompensation
  68. Correction to ‘Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF’ [J Hepatol 2020 (72) 688–701]
  69. The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease
  70. Extracellular vesicle-associated soluble CD163 and CD206 in patients with acute and chronic inflammatory liver disease
  71. Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure
  72. Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease
  73. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
  74. Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis
  75. The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn’s Disease
  76. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF
  77. Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
  78. New tight junction protein 2 variant causing progressive familial intrahepatic cholestasis type 4 in adults: A case report
  79. Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial
  80. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
  81. Plasma chromogranin A (CgA) as a predictor of progression in patients with neuroendocrine tumors.
  82. Time‐dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct‐acting antiviral therapy of chronic hepatitis C
  83. Use of complimentary medicines in patients with neuroendocrine tumors.
  84. Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis
  85. Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial
  86. Insulin resistance, liver inflammation and fibrosis in patients with NAFLD
  87. The macrophage‐related biomarkers sCD163 and sCD206 are released by different shedding mechanisms
  88. 551 OPTIMAL TIMING OF ENDOSCOPY IS ASSOCIATED WITH LOWER 42-DAY MORTALITY IN VARICEAL BLEEDING
  89. Non-alcoholic steatohepatitis, but not simple steatosis, disturbs the functional homogeneity of the liver - a human galactose positron emission tomography study
  90. Macrophage markers soluble CD163 and soluble mannose receptor are associated with liver injury in patients with paracetamol overdose
  91. The Macrophage Activation Marker Soluble CD163 is Associated With Early Allograft Dysfunction After Liver Transplantation
  92. Hepatic exposure of metformin in patients with non‐alcoholic fatty liver disease
  93. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals
  94. FRI-339-Clinical translatability of a diet-induced obese mouse model of non-alcoholic steatohepatitis
  95. PS-023-Factors predicting survival in patients with high-risk acute variceal bleeding treated with pre-emptive (Early)-TIPS
  96. THU-324-Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions
  97. PS-022-Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding
  98. THU-325-Regional liver function investigated by galactose positron emission tomography is reduced in patients with non-alcoholic steatohepatitis
  99. SAT-079-Respiratory infection in patients with cirrhosis and acute variceal bleeding on antibiotic prophylaxis: A multicenter observational study of 2138 patients
  100. FRI-120-Structural liver disease rather than portal hypertension is the predominant factor for hepatic macrophage activation in patients with cirrhosis, portal vein thrombosis and idiopathic portal hypertension
  101. FRI-016-Validation of the PREsTo machine learning algorithm for the prediction of disease progression in patients with primary sclerosing cholangitis
  102. Effects of implementation of a national fast track clinical pathway for hepatocellular carcinoma in western Denmark
  103. Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects
  104. Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions
  105. The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark
  106. P282 Combination of biomarkers reflecting type IV collagen degradation and citrullinated vimentin predicts response to adalimumab with high diagnostic accuracy, in patients with Crohn’s disease
  107. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors
  108. Preemptive‐TIPS Improves Outcome in High‐Risk Variceal Bleeding: An Observational Study
  109. Orchestration of Tryptophan-Kynurenine pathway, acute decompensation and acute-on-chronic liver failure in cirrhosis
  110. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
  111. Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease
  112. Urea cycle dysregulation in non-alcoholic fatty liver disease
  113. High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study
  114. No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial
  115. The Risk of Second Primary Colorectal Adenocarcinomas is not Increased among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms – A Nationwide Population Based Study
  116. The role of IFN in the development of NAFLD and NASH
  117. β-Blockers Improve Presinusoidal Portal Hypertension
  118. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology
  119. No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease
  120. The Effect of Ethanol on Inflammation Markers and FGF-21 in Healthy Individuals
  121. Soluble CD163 correlates with lipid metabolic adaptations in human type 1 diabetes patients during ketoacidosis
  122. Effects of direct-acting antiviral treatment of chronic hepatitis C on macrophage activation, liver stiffness, metabolic liver function and portal hypertension in cirrhosis patients
  123. Albumin administration in the prevention of hepatorenal syndrome (HRS) and death in patients with advanced cirrhosis and non-SBP infections
  124. Combinations of inflammatory markers, soluble (s)CD163, mannose receptor (sMR) and neutrophil gelatinase associated lipocalin (NGAL), predicts mortality in patients with acute-on-chronic liver failure
  125. Epigenetic modification of urea cycle enzymes in NAFLD animal models and patients: Implications for novel therapeutic approaches
  126. Loss of colonization resistance in cirrhosis facilitates proton pump inhibitor-associated oralization of the colonic microbiome
  127. Prognosis in patients with primary biliary cholangitis based on histological stage at diagnosis. A nationwide population-based study
  128. The Galactose Elimination Capacity test may monitor treatment response and disease progression in patients with Wilson Disease
  129. The kynurenine pathway in cirrhosis. Relationship with the development of acute decompensation and acute-on-chronic liver failure, clinical course and mortality
  130. Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease
  131. Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
  132. Adult Presentation of Noncirrhotic Portal Hypertension and Ascites following Treatment for Wilms’ Tumor in Childhood
  133. Preserved liver regeneration capacity after partial hepatectomy in rats with non-alcoholic steatohepatitis
  134. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment
  135. Nutritional status and nutritional risk in patients with neuroendocrine tumors
  136. Cell death markers in patients with cirrhosis and acute decompensation
  137. Unexplained cholestasis in adults and adolescents: diagnostic benefit of genetic examination
  138. Macrophage activation marker sCD163 correlates with accelerated lipolysis following LPS exposure: a human-randomised clinical trial
  139. Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation
  140. The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients
  141. Corrigendum
  142. Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study
  143. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial
  144. Time course of compromised urea synthesis in patients with alcoholic hepatitis
  145. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
  146. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas
  147. High burden of coronary atherosclerosis in patients with cirrhosis
  148. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease
  149. Letter: autoimmune hepatitis-drug-induced liver injury must always be excluded. Authors’ reply
  150. A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors
  151. Isolated congenital hepatic fibrosis associated with TMEM67 mutations: report of a new genotype-phenotype relationship
  152. Enrichment of Genetic Variants in the Glucocorticoid Receptor Signalling Pathway in Autoimmune Hepatitis with Failure of Standard Treatment
  153. Survival and Predictors of Death for Patients with Bronchopulmonary Carcinoid at a Danish Tertiary NET Centre
  154. Men with biopsy-confirmed hepatocellular adenoma have a high risk of progression to hepatocellular carcinoma: A nationwide population-based study
  155. IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis
  156. Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes
  157. Long-Term Ethanol Exposure Decreases the Endotoxin-Induced Hepatic Acute Phase Response in Rats
  158. Time Course of Compromised Urea Synthesis in Patients With Alcoholic Hepatitis
  159. Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease
  160. Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting
  161. Enrichment of genetic variants in the glucocorticoid receptor signalling pathway in standard treatment failure autoimmune hepatitis
  162. Macrophage activation markers sCD163 and mannose receptor predict survival and correlate with markers of gut permeability in patients with liver cirrhosis
  163. Soluble (s)CD163 a macrophage activation marker is associated with liver disease severity in patients with Wilson’s disease
  164. The macrophage activation marker, soluble CD163 is associated with hepatic inflammation and fibrosis in chronic viral hepatitis C and declines during effective direct-acting antiviral therapy
  165. The novel macrophage activation marker soluble Mannose Receptor, and soluble CD163, are elevated after acetaminophen intoxication in relation to liver disease severity
  166. Time course of compromised urea synthesis in patients with alcoholic hepatitis
  167. Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls
  168. A descriptive cross-sectional study of pain in patients with neuroendocrine tumors
  169. Polymorphisms in the IL‐1 gene cluster influence systemic inflammation in patients at risk for acute‐on‐chronic liver failure
  170. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis
  171. The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation
  172. Contrast-enhanced ultrasound compared with computed tomography, magnetic resonance imaging, and positron emission tomography for diagnosing liver metastases in people with newly diagnosed colorectal cancer
  173. Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury
  174. Role of macrophages and macrophage activation marker sCD163 in patients with autoimmune hepatitis
  175. Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis
  176. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C
  177. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure
  178. Alcoholic Hepatitis Markedly Decreases the Capacity for Urea Synthesis
  179. The damage-associated molecular pattern HMGB1 is elevated in human alcoholic hepatitis, but does not seem to be a primary driver of inflammation
  180. Editorial: measuring inflammatory and fibrotic components of portal hypertension - a non-invasive hepatic venous pressure gradient? Authors’ reply
  181. Reduced sCD36 following weight loss corresponds to improved insulin sensitivity, dyslipidemia and liver fat in obese children
  182. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease
  183. Rectal Mechano-sensory Function in Patients with Carcinoid Diarrhea
  184. The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis
  185. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF)
  186. Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease
  187. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure
  188. Effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment
  189. Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease
  190. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease
  191. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
  192. Anti-CD163-dexamethasone conjugate inhibits the acute phase response to lipopolysaccharide in rats
  193. Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease
  194. Adipose Tissue Insulin Resistance is Associated with Macrophage Activation in Non-Diabetic Patients with Non-Alcoholic Fatty Liver Disease
  195. Circulating CD36 Correlates with Intrahepatic Lipid Content in Non-Alcoholic Fatty Liver Disease Patients
  196. Disease-Related Variants in Genes Involved in Bile Formation and Transport Demonstrated in 12 of 22 Patients with “Unexplained Cholestasis” by the Use of a Novel Panel for Genetic Testing
  197. Liver Regeneration Capacity after Partial Hepatectomy in Rats with Non-Alcoholic Steatohepatitis
  198. Macrophage Activation Assessed by Soluble CD163 and Soluble Mannose Receptor is Associated with Liver Injury in Patients with Acetaminophen Overdose
  199. Patients with Liver Cirrhosis Have Similar Prevalence, but Higher Burden of Coronary Artery Disease Compared to Patients Evaluated for Angina Pectoris
  200. Polymorphismus in the Interleukin (IL)-1 Gene Cluster Influence the Inflammatory Burden in Patients with Decompensated Cirrhosis and Acute-On-Chronic Liver Failure
  201. Soluble CD163, a Marker of Macrophage Activation, is Increased in Early Allograft Dysfunction after Liver Transplantation
  202. Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study
  203. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma
  204. Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients
  205. Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center
  206. The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment
  207. Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art
  208. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery
  209. Regional Gastrointestinal Transit Times in Patients With Carcinoid Diarrhea: Assessment With the Novel 3D-Transit System
  210. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis
  211. Monitoring Kidney Function in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC: Associations with Risk Factors
  212. Effect of resveratrol on experimental non-alcoholic steatohepatitis
  213. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure
  214. Macrophage activation in obese children with non-alcoholic fatty liver diease
  215. P0974 : Effects of resveratrol on experimental non-alcoholic steatohepatitis
  216. P1044 : Randomised, placebo-controlled clinical trial: Long-term resveratrol treatment for non-alcoholic fatty liver disease
  217. P1061 : The macrophage activation marker SCD163 and the apoptosis marker cytokeratin-18 are both predictors of disease severity in patients with non-alcoholic fatty liver disease
  218. LP21 : The macrophage activation markers soluble CD206 And CD163 predict mortality in patients with liver cirrhosis and acute-on-chronic liver failure (ACLF)
  219. Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients
  220. Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites
  221. Reply
  222. A Comparison of Three Chromogranin A Assays in Patients with Neuroendocrine Tumours
  223. Soluble CD163, a Specific Macrophage Activation Marker, is Decreased by Anti-TNF-αAntibody Treatment in Active Inflammatory Bowel Disease
  224. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure
  225. Circulating mannan-binding lectin, M-, L-, H-ficolin and collectin-liver-1 levels in patients with acute liver failure
  226. Hepatic Macrophage Activation and the LPS Pathway in Patients With Alcoholic Hepatitis: A Prospective Cohort Study
  227. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
  228. The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children
  229. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
  230. Vitamin B12and its binding proteins in hepatocellular carcinoma and chronic liver diseases
  231. Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function
  232. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C
  233. Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats
  234. P320 ALCOHOLIC HEPATITIS DECREASES THE CAPACITY FOR UREA SYNTHESIS
  235. P1018 MARKERS OF COLLAGEN REMODELING DETECT CLINICALLY SIGNIFICANT FIBROSIS IN CHRONIC HEPATITIS C PATIENTS
  236. P1007 SOLUBLE CD163, A MACROPHAGE ACTIVATION MARKER, IS INDEPENDENTLY ASSOCIATED WITH FIBROSIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS B AND C
  237. P824 SOLUBLE CD163, A MACROPHAGE ACTIVATION MARKER, IS INDEPENDENTLY ASSOCIATED WITH STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
  238. Effects of long-acting somatostatin analogues on redox systems in rat lens in experimental diabetes
  239. Prednisolone but Not Infliximab Aggravates the Upregulated Hepatic Nitrogen Elimination in Patients with Active Inflammatory Bowel Disease
  240. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease
  241. Trefoil factors in inflammatory bowel disease
  242. Chemoembolization of intermediate stage hepatocellular carcinomas: Results from a Nordic tertiary liver cancer center
  243. Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease
  244. No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion
  245. Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience
  246. Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis
  247. 591 BACTERIAL DNA MEASUREMENTS IN PATIENTS WITH CIRRHOSIS UNDERGOING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) INSERTION
  248. 1342 CHANGE IN SOLUBLE CD163, A MARKER OF ACTIVATED MACROPHAGES, IS ASSOCIATED WITH IMPROVEMENT IN LIVER ENZYMES AND METABOLIC PROFILE IN OBESE CHILDREN DURING LIFESTYLE INTERVENTION
  249. 1301 ENDOTOXIN CAUSES HIGH MORTALITY AND REDUCED HEPATIC SYNTHESIS OF ACUTE PHASE PROTEINS IN RATS WITH EXPERIMENTAL NON-ALCOHOLIC FATTY LIVER DISEASE
  250. 1414 THE CLIF-CONSORTIUM SCORE PREDICTS MORTALITY MORE ACCURATELY THAN THE MELD AND MELD-SODIUM SCORES IN PATIENTS HOSPITALIZED WITH DECOMPENSATED CIRRHOSIS WITH AND WITHOUT ACUTE-ON-CHRONIC-LIVER FAILURE (ACLF).
  251. Quantitative histological assessment of hepatic ischemia-reperfusion injuries following ischemic pre- and post-conditioning in the rat liver
  252. Macrophage biomarkers predict prognosis in patients with liver cirrhosis
  253. Regulation of urea synthesis during the acute-phase response in rats
  254. Highest Frequencies of Interleukin-22-Producing T Helper Cells in Alcoholic Hepatitis Patients with a Favourable Short-Term Course
  255. Goblet Cell Carcinoids of the Appendix
  256. Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability
  257. Treatment of Budd-Chiari syndrome with a focus on transjugular intrahepatic portosystemic shunt
  258. Changes in adipokines after transjugular intrahepatic porto-systemic shunt indicate an anabolic shift in metabolism
  259. Small intestinal transit in patients with liver cirrhosis and portal hypertension: a descriptive study
  260. Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel® given by either self/partner or a health care professional
  261. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
  262. Insulin-like Growth Factor-I Concentration and Risk of Prostate Cancer: Results from the European Prospective Investigation into Cancer and Nutrition
  263. Ischemic pre- and postconditioning has pronounced effects on gene expression profiles in the rat liver after ischemia/reperfusion
  264. Gender and age effects on the continuous reaction times method in volunteers and patients with cirrhosis
  265. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis
  266. Effects of long-term experimental diabetes on adrenal gland growth and phosphoribosyl pyrophosphate formation in growth hormone-deficient dwarf rats
  267. Cirrhosis and mortality risks of biopsy-verified alcoholic pure steatosis and steatohepatitis: a nationwide registry-based study
  268. 1371 IL-22 PRODUCING T CELLS ARE ASSOCIATED WITH A FAVOURABLE DISEASE COURSE IN ALCOHOLIC HEPATITIS
  269. 1375 PROGNOSIS OF ALCOHOLIC PURE STEATOSIS AND STEATOHEPATITIS: A NATIONWIDE BIOPSY- AND REGISTRY-BASED STUDY
  270. 723 SOLUBLE CD163, A MARKER FOR MACROPHAGE ACTIVATION, IS NOT ASSOCIATED TO HCC, PER SE BUT PREDICTS DISEASE PROGRESSION
  271. Carvedilol or propranolol in portal hypertension? A randomized comparison
  272. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition
  273. Effect of a 10-week Weight Loss Camp on Fatty Liver Disease and Insulin Sensitivity in Obese Danish Children
  274. Effects of long-acting somatostatin analogues on adrenal growth and phosphoribosyl pyrophosphate formation in experimental diabetes
  275. Incidence and Survival of Patients with Small Intestinal Neuroendocrine Tumours in a Danish NET Center
  276. Goblet Cell Carcinoid in a Patient with Neurofibromatosis Type 1: A Rare Combination
  277. Prognosis and staging of non-alcoholic fatty liver disease
  278. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors
  279. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS
  280. Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland
  281. Effects of ischemic pre- and postconditioning on HIF-1α, VEGF and TGF-β expression after warm ischemia and reperfusion in the rat liver
  282. IL-6 has no acute effect on the regulation of urea synthesisin vivoin rats
  283. Age-dependency of galactose elimination capacity in healthy children and children with chronic liver disease
  284. Expression of genes involved in rat liver angiogenesis after ischaemia and reperfusion: effects of ischaemic pre- and post-conditioning
  285. Creation of a Fistula Between the Hepatic Duct and the Gastric Lumen by way of Percutaneus Transhepatic Cholangiography: A Case Report
  286. Effect of weight reduction on insulin sensitivity, sex hormone-binding globulin, sex hormones and gonadotrophins in obese children
  287. A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC)
  288. Unchanged capacity of urea synthesis during acute phase response in rats
  289. Insulin sensitivity and body composition in cirrhosis: changes after TIPS
  290. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours
  291. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies
  292. Ascites from patients with alcoholic liver cirrhosis contains higher IGF-I bioactivity than serum
  293. 169 CARVEDILOL OR PROPRANOLOL IN PORTAL HYPERTENSION? A RANDOMIZED CLINICAL TRIAL
  294. 514 CIRCULATING SCD163, A SCAVENGER RECEPTOR RELEASED FROM ACTIVATED MACROPHAGES, IS ASSOCIATED WITH PORTAL HYPERTENSION IN PATIENTS WITH LIVER CIRRHOSIS
  295. 586 IMAGING OF NEUROENDOCRINE TUMORS AND LIVER METASTASIS BY F18-DOPA PET SCANNING
  296. Serum levels of IGF‐I, IGFBP‐3 and colorectal cancer risk: results from the EPIC cohort, plus a meta‐analysis of prospective studies
  297. Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis
  298. Tumor necrosis factor-α acutely up-regulates urea synthesisin vivoin rats – a hepatic component of inflammatory catabolism?
  299. Partial Liver Ischemia Is Followed by Metabolic Changes in the Normally Perfused Part of the Liver during Reperfusion
  300. Soluble membrane attack complex in ascites in patients with liver cirrhosis without infections
  301. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats
  302. The Association between Diet and Serum Concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition
  303. 752 EFFECT OF TIPS ON SOLUBLE CD163 IN PATIENTS WITH LIVER CIRRHOSIS
  304. 159 EFFECTS OF ISCHEMIC PRE- AND POSTCONDITIONING ON HIF-1α, VEGF AND TGF-β EXPRESSION DURING WARM LIVER ISCHEMIA AND REPERFUSION
  305. 194 INSULIN SENSITIVITY AND BODY COMPOSITION IN CIRRHOSIS: CHANGES AFTER TIPS
  306. 99 RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH LIVER DISEASE: A NATIONWIDE POPULATION- BASED CASE-CONTROL STUDY
  307. 252 TUMOR NECROSIS FACTOR-ALPHA ACUTELY UP-REGULATES UREA SYNTHESIS IN VIVO IN RATS – A HEPATIC ELEMENT OF INFLAMMATORY CATABOLISM
  308. The IGF system after insertion of a transjugular intrahepatic porto-systemic shunt in patients with liver cirrhosis
  309. Cytokine Changes during Warm Ischemia and Reperfusion of the Pig Liver with or without Preconditioning
  310. Risk of Venous Thromboembolism in Patients With Liver Disease: A Nationwide Population-Based Case–Control Study
  311. The influence of preconditioning on metabolic changes in the pig liver before, during, and after warm liver ischemia measured by microdialysis
  312. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes
  313. sMAC in plasma and ascites from patients with liver cirrhosis
  314. Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: A Danish population-based case-control study
  315. Soluble CD163 from activated macrophages predicts mortality in acute liver failure
  316. Metabolic Changes in the Pigliver During Warm Ischemia and Reperfusion Measured by Microdialysis
  317. 3530 POSTER Preliminary results from GEPTOSIS, the international study on medical treatment practice and outcomes in gastroenteropancreatic (GEP) neuroendocrine tumors (NET): variability in the time between initial diagnosis and treatment of GEP NET
  318. Portal vein thrombosis; risk factors, clinical presentation and treatment
  319. Serum Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3 Concentrations and Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition
  320. Impact of Enteral Supplements Enriched with ω–3 Fatty Acids and/or ω–6 Fatty Acids, Arginine and Ribonucleic Acid Compounds on Leptin Levels and Nutritional Status in Active Crohn’s Disease Treated with Prednisolone
  321. Opposite effects on regulation of urea synthesis by early and late uraemia in rats
  322. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn’s disease: Relations to disease activity and corticosteroid treatment
  323. Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention
  324. Effects of five different alcoholic drinks on patients with Crohn's disease
  325. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition
  326. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease
  327. Serum Trefoil Factors in Patients with Inflammatory Bowel Disease
  328. Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women
  329. Quality improvement in wellness reports in patients with Crohn’s disease
  330. Discharge diagnoses of liver diseases in Nuuk Greenland compared to a Danish county hospital
  331. Associations between the IGF system and inflammatory markers in inflammatory bowel disease
  332. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids
  333. Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis
  334. The Insulin-Like Growth Factor System and Markers of Inflammation in Adult Patients with Inflammatory Bowel Disease
  335. Effects of pure ethanol and alcopops on glucose, insulin, and the insulin-like growth factor system in healthy subjects
  336. Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with ω-3 or ω-6 fatty acids and corticosteroids
  337. The Involvement of Growth Hormone (GH), Insulin-Like Growth Factors (IGFs) and Vascular Endothelial Growth Factor (VEGF) in Diabetic Kidney Disease
  338. The Influence of Amphotericin B and Neomycin on the Effect of Human Relaxin-2 on Foetal Membranes and Isolated Myometrium
  339. Budd‐Chiari and inferior caval vein syndromes due to membranous obstruction of the liver veins: successful treatment with angioplasty and transcaval transjugular intrahepatic porto‐systemic shunt
  340. Combined liver vein and spleen pulp pressure measurements in patients with portal or splenic vein thrombosis
  341. Albumin in vaginal fluid is a marker of infection in early pregnancy
  342. Editorial
  343. Effect of Combination Therapy with a Calcium Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor on Renal Hypertrophy and Urinary Albumin Excretion in Diabetic Rats
  344. Markers of fetal growth and serum levels of insulin-like growth factor (IGF) I, -II and IGF binding protein 3 in adults
  345. Inhibitory effects of octreotide on renal and glomerular growth in early experimental diabetes in mice
  346. Low free and total insulinlike growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment
  347. Effects of octreotide on serum insulin-like growth factor I and insulin-like growth factor binding proteins in patients with cirrhosis
  348. Lessons Learned From Lymphocytes: CC Chemokine Receptor-7 Involved in Lymphogenic Metastasis of Melanoma
  349. Signaling lymphocytic activation molecule (SLAM) regulates T cellular cytotoxicity
  350. Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor β receptor expression in experimental diabetes in rats
  351. Inhibition of Major Histocompatibility Complex Class II-Dependent Antigen Presentation by Neutralization of Gamma Interferon Leads to Breakdown of Resistance against Measles Virus-Induced Encephalitis
  352. Comparison of the effects of nitrendipine and enalapril on development and progression of diabetic glomerulopathy in streptozotocin-diabetic rats
  353. Effect of nitrendipine and nisoldipine on renal structure and function in long-term experimental diabetes in rats
  354. Serum markers for hepatic fibrosis in chronic hepatitis C
  355. The Renal Expression of Transforming Growth Factor-  Isoforms and Their Receptors in Acute and Chronic Experimental Diabetes in Rats
  356. Effect of the calcium channel blocker nitrendipine in normotensive and spontaneously hypertensive, diabetic rats on kidney morphology and urinary albumin excretion
  357. The Calcium Channel Blocker Nitrendipine Attenuates Renal and Glomerular Hypertrophy in Diabetic Rats
  358. Developmental Changes in Serum Levels of Free and Total Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 and -3, and the Acid-Labile Subunit in Rats
  359. Effect of immunosuppression on kidney and serum insulin-like growth factor-I (IGF-I), IGF binding proteins, and renal growth following unilateral nephrectomy in rats
  360. Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats
  361. Growth hormone administration can improve growth in glucocorticoid-injected rats without affecting the lymphocytopenic effect of the glucocorticoid
  362. Diabetic kidney disease: the role of growth factors
  363. Herpesvirus Saimiri Transforms Human T-Cell Clones to Stable Growth without Inducing Resistance to Apoptosis
  364. Differential expression of renal growth hormone receptor and its binding protein in experimental diabetes mellitus
  365. Effect of octreotide, captopril or insulin on renal changes and UAE in long-term experimental diabetes
  366. The Role of Growth Hormone, Insulin-Like Growth Factors, Epidermal Growth Factor and Transforming Growth Factor β in Diabetic Kidney Disease: An Update
  367. Effect of GH/IGF-I deficiency on long-term renal changes and urinary albumin excretion in diabetic dwarf rats
  368. Effect of graded renal ablation on kidney and serum insulin-like growth Factor-I (IGF-I) and IGF binding proteins in rats: Relation to compensatory renal growth
  369. The Role of Growth Factors in Diabetic Kidney Disease
  370. Increased number of myocardial voltage-gated Ca2+ channels and unchanged total  -receptor number in long-term streptozotocin-diabetic rats
  371. Effect of hyperthyroidism on circulating levels of free and total IGF-I and IGFBPs in rats
  372. The role of growth hormone, insulin-like growth factors (IGFs), and IGF-binding proteins in experimental diabetic kidney disease
  373. Effect of octreotide on experimental diabetic renal and glomerular growth: importance of early intervention
  374. Effect of Diabetes and Dietary Ubiquinone Supplementation on the Post-translational Modification of Rat Lens βL Crystallin
  375. Expression of insulin-like growth factor binding proteins in the rat kidney: effects of long-term diabetes.
  376. Expression of insulin-like growth factor binding proteins in the rat kidney: effects of long-term diabetes
  377. Effect of sodium selenite on growth, insulin-like growth factor-binding proteins and insulin-like growth factor-I in rats
  378. Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats
  379. Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats
  380. Lanreotide, a somatostatin analogue, reduces insulin-like growth factor I accumulation in proliferating aortic tissue in rabbits in vivo. A preliminary study
  381. Roles of Growth Factors in Diabetic Kidney Disease
  382. Selenium in the central nervous system of rats exposed to 75-Sel-selenomethionine and sodium selenite
  383. Increased ornithine decarboxylase activity in kidneys undergoing hypertrophy in experimental diabetes
  384. Selenium complexes in the anterior pituitary of rats exposed to L-selenomethionine